Literature summary for 3.4.21.77 extracted from

Elliott, C.S.; Shinghal, R.; Presti, J.C.
The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes (2009), Clin. Cancer Res., 15, 4694-4699.

Search for more literature for 3.4.21.77

Application

Application	Comment	Organism
medicine	decreases in prostate volume over time and the resultant change in prostate-specific antigen performance characteristics may have contributed a bias toward the detection of high-grade disease in the finasteride arm of the Prostate Cancer Prevention Trial. Performance of prostate specific antigen for the detection of any cancer and high-grade cancer is affected by prostate size: prostate-specific antigen performance is significantly better in men with smaller prostates for both the detection of low-grade and high-grade disease	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
serum	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
prostate-specific antigen	-	Homo sapiens
PSA	-	Homo sapiens

General Information

General Information	Comment	Organism
physiological function	prostate-specific antigen levels between various diagnoses of cancer and size strata have minimal variation. In patients with prostate volumes greater than 50 cm3, prostate-specific antigen density levels have minimal variation between any histologic diagnosis, benign or malignant. The median prostate-specific antigen density levels in men without cancer in small or intermediate prostates (greater than 30 cm3 and 30-50 cm3, respectively) are similar. The prostate-specific antigen density in patients with cancer (low or high grade) is significantly higher in smaller prostates compared with intermediate-sized prostates	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)